Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0024312 (
lymphopenia
)
4,859
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Background:
Loss of function mutations in
SGPL1
are associated with Sphingosine-1-phosphate lyase insufficiency syndrome, comprising steroid resistant nephrotic syndrome, and primary adrenal insufficiency (PAI) in the majority of cases.
SGPL1
encodes sphingosine-1-phosphate lyase (SGPL1) which is a major modulator of sphingolipid signaling.
Case Presentation:
A Pakistani male infant presented at 5 months of age with failure to thrive, nephrotic syndrome, primary adrenal insufficiency, hypothyroidism, and hypogonadism. Other systemic manifestations included persistent
lymphopenia
, ichthyosis, and motor developmental delay. Aged 9 months, he progressed rapidly into end stage oligo-anuric renal failure and subsequently died. Sanger sequencing of the entire coding region of
SGPL1
revealed the novel association of a rare homozygous mutation (chr10:72619152, c.511A>G, p.N171D;
MAF
-1.701e-05) with the condition. Protein expression of the p.N171D mutant was markedly reduced compared to
SGPL1
wild type when overexpressed in an
SGPL1
knockout cell line, and associated with a severe clinical phenotype.
Conclusions:
The case further highlights the emerging phenotype of patients with loss-of-function
SGPL1
mutations. Whilst nephrotic syndrome is a recognized feature of other disorders of sphingolipid metabolism, sphingosine-1-phosphate lyase insufficiency syndrome is unique amongst the sphingolipidoses in presenting with multiple endocrinopathies. Given the multi-systemic and progressive nature of this form of PAI/ nephrotic syndrome, a genetic diagnosis is crucial for optimal management and appropriate screening for comorbidities in these patients.
...
PMID:A Sphingosine-1-Phosphate Lyase Mutation Associated With Congenital Nephrotic Syndrome and Multiple Endocrinopathy. 3232 66